TRVI241220C7000
- 0.00
- 0.000.00%
Trevi Therapeutics Newsroom
A Quick Look at Today's Ratings for Trevi Therapeutics(TRVI.US), With a Forecast Between $6 to $9
Trevi Therapeutics Price Target Raised to $7.50/Share From $6.00 by HC Wainwright & Co.
Trevi Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Trevi Therapeutics Analyst Ratings
Optimistic Buy Rating for Trevi Therapeutics Amid Promising Phase 2b Trial Results
Oppenheimer Remains a Buy on Trevi Therapeutics (TRVI)
B.Riley Financial Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $6
D. Boral Capital Maintains Buy on Trevi Therapeutics, Maintains $21 Price Target
Trevi Therapeutics Price Target Maintained With a $8.00/Share by Needham
Trevi Therapeutics Analyst Ratings
JonesTrading Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $8
B.Riley Financial Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $6
Needham Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $8
Stifel Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Announces Target Price $8
Trevi Therapeutics Price Target Maintained With a $21.00/Share by EF Hutton
Trevi Therapeutics Is Maintained at Buy by EF Hutton
Trevi Therapeutics Analyst Ratings
JonesTrading Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $8
H.C. Wainwright Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $6
Trevi Therapeutics Price Target Maintained With a $21.00/Share by EF Hutton